Results 171 to 180 of about 240,433 (353)

Data from <i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

, 2023
Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, Danxia Ke, Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock   +18 more
openalex   +1 more source

Risk of Radiation-Associated Secondary Malignancies among Patients with Breast Cancer Harboring TP53 Germline Variants [PDF]

, 2023
G. Cederquist, Lillian A. Boe, Michael F. Walsh, Zsofia K. Stadler, Amy Xu, Boris Mueller, D.A. Roth O'Brien, M. Bernstein, John Cuaron, S.F. Bakhoum, Simon N. Powell, Atif J. Khan, Mark E. Robson, Kara N. Maxwell, Neil K. Taunk, Lior Z. Braunstein   +15 more
openalex   +1 more source

Molecular characterization of the A52 murine hepatocellular carcinoma cell line

Animal Models and Experimental Medicine, EarlyView.
Hepatocellular carcinoma (HCC) is a poor outcome cancer with limited therapeutic choices. To advance therapeutic development we genetically characterized the A52 murine HCC cell line. We noted genetic changes that match a subset of human HCC and this offers the opportunity to test novel targeted therapies in syngeneic mice.
Rhys Gillman, Eun Jin Sun, Miriam Wankell, Matt A. Field, Ulf Schmitz, Lionel Hebbard   +5 more
wiley   +1 more source

Data from Mouse Homolog of the Human <i>TP53</i> R337H Mutation Reveals Its Role in Tumorigenesis

, 2023
Jihoon Park, Jie Li, Matthew F. Starost, Chengyu Liu, Jie Zhuang, Jichun Chen, Maria Isabel Achatz, Ju‐Gyeong Kang, Pingyuan Wang, Sharon A. Savage, Paul M. Hwang   +10 more
openalex   +1 more source

Deep reinforcement learning for diagnosing various types of cancer by TP53 mutation patterns [PDF]

, 2021
Armaqan Rahmani, Behrouz Minaei‐Bidgoli, Meysam Ahangaran   +2 more
openalex   +1 more source

From Basics to Benchmarks: Evaluating Sample Adequacy, PD‐L1 Expression, and Molecular Profiling in Effusion Samples of Lung Adenocarcinoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Introduction Lung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing.
Harpreet Virk, Claire Michael, Keri Ann Pfeil, Navid Sadri, Omid Savari, Aparna Harbhajanka   +5 more
wiley   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

American Journal of Hematology, EarlyView.
Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids   +16 more
wiley   +1 more source

Urolithin A, a Diet‐Derived Gut Microbial Metabolite Against Pulmonary Hypertension Identified via Molecular Docking, Molecular Dynamics and Surface Plasmon Resonance

Food Safety and Health, EarlyView.
Urolithin A, a gut microbial metabolite, binds TNF to suppress proliferation, inflammation, and oxidative stress, offering a promising microbe‐derived therapeutic avenue for pulmonary hypertension. ABSTRACT Pulmonary hypertension (PH) is a complex and multifactorial disease that poses a significant clinical challenge.
Yujie Qu, Yinghua Huo, Yichen Wang, Yao Mu, Xue Yu, Leiyu Tian, Jian Guo, Xuezhi Yang, Yucai Chen   +8 more
wiley   +1 more source

Mapping of TP53 protein network using cytoscape software

Pharmaceutical and Biomedical Research, 2018
TP53 acts as a tumor suppressor in cancer. It induces cell cycle arrest or apoptosis in response to cellular stress and damage. p53 gene alteration could cause uncontrolled cell proliferation.In the present study, we used TP53 gene as the seed in the ...
Asita Elengoe, Salehhuddin Hamdan
doaj  

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source